nach oben

memo - Magazine of European Medical Oncology

Tipp

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

verfasst von: Dr. Daniel Heintel

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

At the 2017 American Society of Hematology (ASH) meeting partly standards-changing data in the treatment of hematological malignancies were presented. More than 5000 scientific abstracts are submitted each year and more than 3000 abstracts are accepted for oral and poster presentations through an extensive peer review process. In this issue of memo five hematologists summarized their personal highlights in their respective areas of expertise. …

Vorheriger Artikel The adolescence of cancer immunotherapy: from a difficult childhood to a pillar of modern anticancer therapy

Nächster Artikel Educational no. 1: Bone marrow diagnostics in hemato-oncological diseases

Titel: Update and clinical highlights presented at the 2017 American Society of Hematology Meeting
verfasst von: Dr. Daniel Heintel
Publikationsdatum: 01.06.2018
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0417-x

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

Excerpt

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Update of clinical highlights presented at the 2017 American Society of Hematology Meeting

My burning issues in aggressive Non Hodgkin’s Lymphoma

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms

Chronic lymphocytic leukemia at ASH 2017

Management of adverse events related to checkpoint inhibition therapy

Chimeric antigen receptor T‑cell therapy—a hematological success story